Link Between Gout and Dry Eye Disease: Systemic Inflammation and Ocular Surface Impact
Overview
Recent evidence highlights a significant association between gout and dry eye disease (DED), driven by systemic inflammation and deposition of monosodium urate crystals in ocular tissues. Understanding this link is crucial for early detection and comprehensive management of patients presenting with both conditions.
Background
Gout is a systemic inflammatory arthritis characterized by elevated uric acid and monosodium urate crystal deposition, primarily affecting joints but also extra-articular tissues including the eye. Dry eye disease is a multifactorial ocular surface disorder influenced by systemic inflammation, which destabilizes the tear film and damages ocular surface structures. Chronic systemic inflammatory diseases such as rheumatoid arthritis and lupus have established associations with DED, and emerging research now implicates gout as another systemic contributor. The overlapping lifestyle and metabolic risk factors for gout and DED further support a shared pathophysiological basis.
Data Highlights
In the United States, approximately 9.2 million people are affected by gout, predominantly males and individuals over 60 years of age. High-sociodemographic index regions report rising gout prevalence due to dietary habits, obesity, metabolic syndrome, sedentary lifestyle, and alcohol consumption. Systemic inflammatory mediators such as TNF-α, IL-6, and MMPs contribute to ocular surface damage and tear film instability in DED patients with systemic inflammation. The NLRP3-IL-1β signaling pathway activated in gout exacerbates ocular surface inflammation, linking systemic uric acid elevation to dry eye pathology.
Key Findings
- Monosodium urate crystals, hallmark of gout, can deposit in ocular tissues contributing to local inflammation.
- Systemic inflammation in gout activates pathways (e.g., NLRP3-IL-1β) that exacerbate ocular surface inflammation and dry eye symptoms.
- DED in gout patients is associated with increased pro-inflammatory cytokines (TNF-α, IL-6) and matrix metalloproteinases that damage corneal epithelium and destabilize tear film.
- Lifestyle factors influencing gout (diet, alcohol, sedentary behavior) also impact dry eye disease, suggesting potential for holistic management.
- Comprehensive DED evaluation should include tear film assessment, ocular surface staining, meibography, and inflammatory biomarkers, alongside systemic health review.
- Multidisciplinary co-management with rheumatologists and primary care providers is essential to control systemic inflammation and improve ocular outcomes.
Clinical Implications
Clinicians should maintain a high index of suspicion for dry eye symptoms in patients with gout and perform thorough ocular surface evaluations. Addressing systemic inflammation through coordinated care and lifestyle modifications may mitigate dry eye severity. Utilizing inflammatory biomarkers and advanced diagnostics can guide personalized treatment strategies targeting both systemic and ocular components.
Conclusion
The emerging link between gout and dry eye disease underscores the importance of recognizing systemic inflammation as a shared pathogenic mechanism. Integrating systemic disease management with targeted ocular therapies offers a promising approach to improve patient quality of life.
References
- TFOS DEWS II Report 2017 -- Dry Eye Disease and Systemic Inflammation
- Chen et al. 2024 -- Gout and Ocular Surface Inflammation
- Nichols KK 2025 -- Ocular Surface News April Edition
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.